SCHEMBL6472928

SCHEMBL6472928

CCOC(=O)/C=C/c1ccc(OC)c(-c2cc3c(cc2OCc2cccc(O)c2)C(C)(C)CCC3(C)C)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 4/20 0.49
CA7 P43166 4/20 0.49
CA9 Q16790 4/20 0.49
CA14 Q9ULX7 4/20 0.49
CA4 P22748 3/20 0.49
CA6 P23280 3/20 0.49
CA5A P35218 3/20 0.49
CA5B Q9Y2D0 3/20 0.49
FDPS P14324 1/20 0.48
MAOB P27338 1/20 0.48
TTR P02766 4/20 0.43
AKR1B10 O60218 2/20 0.42
AKR1B1 P15121 2/20 0.42
ACHE P22303 4/20 0.42
BCHE P06276 3/20 0.42
CA1 P00915 2/20 0.42
APP P05067 1/20 0.42
MAPT P10636 1/20 0.42
RXRA P19793 1/20 0.41
AKR1C4 P17516 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6472933 1.00 CA12 (0.49) CA12CA7CA9CA14CA4
SCHEMBL6477344 0.92 FDPS (0.48) CA12CA7CA9CA14CA4
SCHEMBL6477343 0.92 FDPS (0.48) CA12CA7CA9CA14CA4
SCHEMBL6472256 0.92 FDPS (0.51) CA12CA7CA9CA14CA4
SCHEMBL6472257 0.92 FDPS (0.51) CA12CA7CA9CA14CA4
SCHEMBL6477948 0.90 FDPS (0.50) CA12CA7CA9CA14CA4
SCHEMBL6477944 0.90 FDPS (0.50) CA12CA7CA9CA14CA4
SCHEMBL6472796 0.89 AKR1C3 (0.52) CA9CA5AAPPRXRAAKR1C4
SCHEMBL6472794 0.89 AKR1C3 (0.52) CA9CA5AAPPRXRAAKR1C4
SCHEMBL6473700 0.89 FDPS (0.45) CA12CA7CA9CA14CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6924388-B2 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-02 US disclosed
US-20040092594-A1 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2004-05-13 US disclosed
US-6632963-B1 Are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2003-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092594-A1 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof AHR, TYR, MC1R CA12 4307/4885CA7 2700/4885CA9 3344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.